FY2025 Earnings Forecast for Savara Inc Issued By HC Wainwright (NASDAQ:SVRA)

Savara Inc (NASDAQ:SVRA) – Research analysts at HC Wainwright lowered their FY2025 EPS estimates for Savara in a report released on Tuesday, October 1st. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.46) per share for the year, down from their previous estimate of ($0.44). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Savara’s FY2026 earnings at ($0.34) EPS, FY2027 earnings at $0.01 EPS and FY2028 earnings at $0.23 EPS.

Other analysts have also issued research reports about the stock. JMP Securities reissued a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research report on Tuesday. Guggenheim boosted their price target on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Finally, Oppenheimer boosted their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Savara has an average rating of “Buy” and an average price target of $11.17.

Savara Stock Performance

NASDAQ SVRA opened at $3.82 on Thursday. The company’s 50 day moving average is $4.28 and its 200-day moving average is $4.44. Savara has a 12-month low of $3.12 and a 12-month high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $527.88 million, a P/E ratio of -10.32 and a beta of 0.97.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01).

Hedge Funds Weigh In On Savara

Several hedge funds have recently bought and sold shares of SVRA. Superstring Capital Management LP purchased a new position in Savara during the fourth quarter valued at approximately $3,827,000. Wellington Management Group LLP purchased a new position in Savara in the 4th quarter worth approximately $9,683,000. Sivia Capital Partners LLC purchased a new position in Savara in the 4th quarter worth approximately $169,000. China Universal Asset Management Co. Ltd. grew its stake in Savara by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after buying an additional 10,381 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Savara by 92.3% in the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after buying an additional 35,269 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.